AUVYRON EDUCATION
Tirzepatide: Research Overview
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in metabolic research, including glucose regulation, body-weight outcomes and related cardiometabolic measures.
Tirzepatide Research Evidence
1. What Tirzepatide Is
3. Major Clinical Programs
1. What Tirzepatide Is
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Published research has examined its effects on glucose regulation, body weight and related cardiometabolic measures.
2. Regulatory Status
3. Major Clinical Programs
1. What Tirzepatide Is
In the United States, tirzepatide is FDA-approved under different brand indications for type 2 diabetes, chronic weight management and moderate-to-severe obstructive sleep apnea in certain adults with obesity.
3. Major Clinical Programs
3. Major Clinical Programs
4. Doses Evaluated in Research
The SURPASS program studied tirzepatide mainly in adults with type 2 diabetes. The SURMOUNT program studied outcomes in adults with obesity or overweight, including participants without diabetes.
4. Doses Evaluated in Research
4. Doses Evaluated in Research
4. Doses Evaluated in Research
Major phase 3 trials evaluated once-weekly maintenance doses of 5 mg, 10 mg and 15 mg. Participants underwent gradual dose escalation before reaching the assigned maintenance group. These schedules describe published trial methodology and are not dosing recommendations.
5. Reported Outcomes
4. Doses Evaluated in Research
5. Reported Outcomes
Published trials reported meaningful reductions in body weight and improvements in glucose-related measures. Results varied according to the population studied, dose group, trial duration and comparator.
6. Safety Findings
4. Doses Evaluated in Research
5. Reported Outcomes
The most frequently reported adverse events were gastrointestinal, including nausea, diarrhea and vomiting, particularly during dose escalation. FDA labeling also includes important contraindications, warnings and a boxed warning regarding thyroid C-cell tumors observed in rats.
Published Research Highlights
1. SURPASS Program
The SURPASS trials evaluated tirzepatide mainly in adults with type 2 diabetes. Published findings included improvements in glycated hemoglobin and reductions in body weight across multiple treatment groups.
2. SURMOUNT Program
The SURMOUNT trials evaluated tirzepatide in adults with obesity or overweight, including populations without diabetes. SURMOUNT-1 followed participants for 72 weeks.
3. Body-Weight Outcomes
At 72 weeks in SURMOUNT-1, mean body-weight reductions were 15.0%, 19.5% and 20.9% in the 5 mg, 10 mg and 15 mg groups, respectively, compared with 3.1% with placebo. These figures represent clinical-trial group averages and do not predict individual outcomes.
4. Glucose-Related Outcomes
In adults with type 2 diabetes, clinical trials reported significant reductions in glycated hemoglobin. SURPASS-2 also compared tirzepatide with once-weekly semaglutide.
5. Longer-Term Research
A three-year analysis in participants with obesity and prediabetes reported sustained body-weight reductions and examined progression to type 2 diabetes.
6. Research Limitations
Results should be interpreted according to the population studied, trial duration, comparator, lifestyle intervention and eligibility criteria. Published trial findings do not predict the outcome for every individual.
Scientific References & Research Disclaimer
1. Research Sources
This guide summarizes peer-reviewed clinical research, official regulatory documents and published study reports related to tirzepatide. Sources were selected to reflect both established evidence and current clinical use.
2. Primary Publications
Key sources include the SURPASS and SURMOUNT programs published in The New England Journal of Medicine, along with official U.S. Food and Drug Administration documentation.
3. Educational Use
This content is provided for educational and research-information purposes only. It is not medical advice, dosing guidance or instructions for human use.
4. Research Use Only
For Research Use Only. Not for Human Consumption.
Quality. Innovation. Excellence.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.